RecruitingObesity & Overweight
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
Sponsor: Gila Therapeutics, Inc.
You may qualify if…
- ✓ Body Mass Index 30 to 45
You may not qualify if…
- ✕ Type 2 Diabetes Mellitus
- ✕ Multiple Endocrine Neoplasia Type 2
- ✕ Medullary thyroid cancer
Where it's recruiting
Minnesota
Minneapolis
Source: ClinicalTrials.gov · NCT07728383 · last updated 2026-07-27